STOCK TITAN

Spyre Therapeutics Announces Grants of Inducement Awards

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on antibody engineering for IBD and immune-mediated diseases treatment, has announced new equity inducement awards. The company's independent Compensation Committee approved stock options to purchase 93,200 shares for five non-executive employees under their 2018 Equity Inducement Plan.

The stock options were granted on April 1, 2025, with a 10-year term and an exercise price of $15.295 per share, matching Spyre's closing price on that date. The vesting schedule includes 25% after the first year of employment, followed by monthly vesting of 1/48th of the shares, contingent on continued service with the company.

Spyre Therapeutics (NASDAQ: SYRE), un'azienda biotech in fase clinica focalizzata sull'ingegneria degli anticorpi per il trattamento delle malattie infiammatorie intestinali e delle malattie mediate dal sistema immunitario, ha annunciato nuovi premi azionari. Il Comitato per la Compensazione indipendente dell'azienda ha approvato opzioni su azioni per l'acquisto di 93.200 azioni per cinque dipendenti non esecutivi nell'ambito del loro Piano di Incentivazione Azionaria del 2018.

Le opzioni su azioni sono state concesse il 1 aprile 2025, con una durata di 10 anni e un prezzo di esercizio di $15.295 per azione, corrispondente al prezzo di chiusura di Spyre in quella data. Il piano di maturazione prevede il 25% dopo il primo anno di impiego, seguito da una maturazione mensile di 1/48 delle azioni, a condizione di continuare il servizio presso l'azienda.

Spyre Therapeutics (NASDAQ: SYRE), una empresa biotecnológica en etapa clínica centrada en la ingeniería de anticuerpos para el tratamiento de enfermedades inflamatorias intestinales y enfermedades mediadas por el sistema inmunológico, ha anunciado nuevos premios de incentivos en acciones. El Comité de Compensación independiente de la empresa aprobó opciones sobre acciones para comprar 93,200 acciones para cinco empleados no ejecutivos bajo su Plan de Incentivos en Acciones de 2018.

Las opciones sobre acciones se otorgaron el 1 de abril de 2025, con un plazo de 10 años y un precio de ejercicio de $15.295 por acción, coincidiendo con el precio de cierre de Spyre en esa fecha. El calendario de adquisición incluye un 25% después del primer año de empleo, seguido de una adquisición mensual de 1/48 de las acciones, condicionado a la continuación del servicio con la empresa.

Spyre Therapeutics (NASDAQ: SYRE), 장기 임상 단계의 생명공학 회사로, 염증성 장질환 및 면역 매개 질환 치료를 위한 항체 공학에 집중하고 있으며, 새로운 주식 유인 보상을 발표했습니다. 회사의 독립 보상위원회는 93,200주를 구매할 수 있는 주식 옵션을 2018년 주식 유인 계획에 따라 다섯 명의 비임원 직원에게 승인했습니다.

주식 옵션은 2025년 4월 1일에 부여되었으며, 10년의 기간과 주당 $15.295의 행사 가격이 설정되어 있으며, 이는 해당 날짜의 Spyre 종가와 일치합니다. 주식의 베스팅 일정은 첫 해 근무 후 25%, 이후 매월 1/48의 주식이 베스팅되며, 이는 회사에서의 지속적인 근무에 따라 달라집니다.

Spyre Therapeutics (NASDAQ: SYRE), une entreprise biopharmaceutique en phase clinique axée sur l'ingénierie des anticorps pour le traitement des maladies inflammatoires de l'intestin et des maladies médiées par le système immunitaire, a annoncé de nouvelles récompenses d'incitation en actions. Le Comité de Rémunération indépendant de l'entreprise a approuvé des options d'achat d'actions pour 93 200 actions pour cinq employés non exécutifs dans le cadre de leur Plan d'Incitation en Actions de 2018.

Les options d'achat d'actions ont été accordées le 1er avril 2025, avec une durée de 10 ans et un prix d'exercice de 15,295 $ par action, correspondant au prix de clôture de Spyre à cette date. Le calendrier d'acquisition comprend 25 % après la première année d'emploi, suivi d'une acquisition mensuelle de 1/48 des actions, sous réserve d'un service continu au sein de l'entreprise.

Spyre Therapeutics (NASDAQ: SYRE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Antikörpertechnik zur Behandlung von entzündlichen Darmerkrankungen und immunvermittelten Erkrankungen konzentriert, hat neue Aktienanreizpreise bekannt gegeben. Der unabhängige Vergütungsausschuss des Unternehmens genehmigte Aktienoptionen zum Kauf von 93.200 Aktien für fünf nicht-executive Mitarbeiter im Rahmen ihres Aktienanreizplans von 2018.

Die Aktienoptionen wurden am 1. April 2025 gewährt, mit einer Laufzeit von 10 Jahren und einem Ausübungspreis von 15,295 $ pro Aktie, was dem Schlusskurs von Spyre an diesem Tag entspricht. Der Vesting-Zeitplan umfasst 25 % nach dem ersten Jahr der Anstellung, gefolgt von einer monatlichen Vesting von 1/48 der Aktien, abhängig von der fortgesetzten Dienstzeit im Unternehmen.

Positive
  • None.
Negative
  • None.

WALTHAM, Mass., April 4, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 93,200 shares of common stock of Spyre to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan"). The stock options were approved on April 1, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted with a 10-year term and an exercise price equal to $15.295, the closing price per share of Spyre's common stock as reported by Nasdaq on April 1, 2025. The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee's start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The stock options are subject to the terms of the 2018 Plan.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com.

Spyre Therapeutics, Inc. (PRNewsfoto/Spyre Therapeutics, Inc.)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-announces-grants-of-inducement-awards-302421140.html

SOURCE Spyre Therapeutics, Inc.

FAQ

How many shares are included in Spyre Therapeutics' (SYRE) latest stock option grants?

Spyre Therapeutics granted stock options to purchase 93,200 shares of common stock to five non-executive employees.

What is the exercise price for SYRE's April 2025 stock option grants?

The stock options were granted with an exercise price of $15.295, matching Spyre's closing share price on April 1, 2025.

What is the vesting schedule for Spyre Therapeutics' (SYRE) April 2025 inducement awards?

The options vest 25% after one year, followed by 1/48th monthly vesting, subject to continued employment.

How long is the term of SYRE's April 2025 stock option grants?

The stock options were granted with a 10-year term.
Spyre Therapeutics

NASDAQ:SYRE

SYRE Rankings

SYRE Latest News

SYRE Stock Data

721.50M
52.44M
8.72%
101.11%
16.63%
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM